List view / Grid view
The recent developments in microfluidic technology have provided an effective microreactor platform for the production of a range of pharmaceutically related materials in both nano- and micro-scale. This can be attributed to the unique characteristics that microfluidic-based reactors offer in terms of controllability and uniformity of the material characteristics, compared…
29 September 2014 | By SIGMOID PHARMA LIMITED
SIGMOID PHARMA LIMITED and Pendopharm have entered into agreements concerning a licence for exclusive rights to commercialise CyCol® in the Canadian market and an equity investment in SIGMOID...
23 September 2014 | By Horizon Discovery
Horizon Discovery Group plc announces its interim results for the six months ended 30 June 2014...
5 August 2014 | By Roche
Roche announced that it has agreed to acquire Santaris Pharma, a privately held biopharmaceutical company based near Copenhagen, Denmark...
17 July 2014 | By Pfizer
Pfizer Inc. and InnoPharma, Inc. announced that they have entered into an agreement under which Pfizer will acquire InnoPharma...
15 July 2014 | By BioStrata
For those that couldn’t attend, here is a summary of some of the interesting insights shared at ELRIG’s recent Robotics and Automation 2014 Conference.
7 July 2014 | By Oxford Global
Oxford Global Q&A Session with Brian Pollok, Entrepreneur-In-Residence, University of Virginia...
19 May 2014 | By PerkinElmer
The Opera Phenix™ delivers uncompromising speed and sensitivity, accelerating the understanding of disease and discovery of new and more effective treatment therapies...
Although this target class is already heavily investigated, there are still a significant number of opportunities for discovery of novel drugs targeting additional GPCRs. In this review, scientists from AstraZeneca R&D discuss the general build-up of GPCR screening cascades for discovery of chemical leads that can be further developed into…
The ability to individualise a patient’s care has become a particularly pressing issue in the field of cancer therapeutics as there is a growing recognition that both the global incidence of cancer is steadily rising and the associated costs in terms of treatment and lost productivity are ever increasing. Advances…
Oceans cover 70 per cent of planet Earth and it is only in the 20th century that organisms from this environment began to be assessed for their potential to provide new drugs. A new marine derived pharmaceutical pipeline has started flowing, delivering new chemical entities with unique modes of action…
Preclinical drug target validation has the aim to increase confidence in a particular drug target. The process proves the initial hypothesis that a particular molecular target is key or even causative for pathogenic or symptomatic mechanisms in a disease. Several success factors seem to be of particular importance for the…
Chemokines orchestrate leukocyte trafficking in the immune system, but unregulated or inappropriate chemokine activity plays a key role in many inflammatory, allergic and autoimmune diseases as well as metastatic tumour progression. The chemokine network is comprised of ~50 distinct ligands that specifically bind and activate a family of 20 G…
28 March 2014 | By Freddy White, Drug Target Review
Freddy White, Director, European Pharmaceutical Review & Drug Target Review speaks with Rohit Shroff, Application Specialist, Tecan at Pittcon 2014...
28 March 2014 | By Freddy White, Drug Target Review
Freddy White, Director, European Pharmaceutical Review & Drug Target Review Speaks With Richard Ladd, Senior Director pharmaceutical operations, Waters at Pittcon 2014...
